Excell Celebrates Over 25 Years of Delivering Compassionate Home Care and Hospice Support
06/06/2025, Oklahoma City, Oklahoma // PRODIGY: Feature Story //
Excell, a name synonymous with compassionate and comprehensive care in Oklahoma, is celebrating over 25 years in the space. It is a major milestone that marks a journey of purpose, progress, and people-first service. With two distinct divisions: Excell Private Care Services (PCS) and Excell Home Care & Hospice, the company has grown exponentially over the past eight years under the leadership of the Pennant Group, which acquired the organization in 2017.
What began as a unified home care and hospice service has evolved into two powerhouse branches operating with a shared mission: to be Oklahoma's one-stop-shop solution for in-home medical support across all ages and stages of life.
Excell Private Care Services
Since the Pennant Group acquisition, Excell PCS has seen unprecedented growth. Now operating three additional locations across Oklahoma with numerous patient flows annually, this branch has become a trusted resource for families seeking up to 24-hour support for loved ones, whether recovering from surgery, managing chronic illness, or navigating the challenges of aging.
With a huge team of skilled professionals, including nurses, caregivers, and case managers, Excell PCS has also introduced new service lines tailored to veterans and families on a budget to ensure high-quality care that isn't reserved only for the privileged few.
In an industry often criticized for financial barriers, Excell stands apart by eliminating deposits, upfront nurse visit charges, and long-term contracts. 'When someone is ill or nearing the end of life, it's already an emotional and financial strain,' said Crystal Warner, CEO of Excell PCS. 'We believe care should ease stress, not add to it.'
Excell's 24-hour nurse access, critical during the COVID-19 pandemic, remains a cornerstone of its approach, allowing families to avoid unnecessary ER visits and receive immediate advice in the comfort and safety of their homes.
Excell Home Care & Hospice
On the hospice side, Excell has redefined what end-of-life care looks like in Oklahoma. The organization has expanded its nursing team, built strong community partnerships, and, most importantly, prioritized keeping patients at home longer and out of hospitals.
Unlike traditional home health and hospice models, Excell offers 24/7 support, not just to patients but to their families as well, sending caregivers to sit with loved ones so relatives can rest, grieve, or simply breathe. 'Families often fear hospice because it signals the end,' said Kristina Tell, RN and Executive Director of Excell Home Care & Hospice. 'We see it as an opportunity to bring peace, presence, and support when people need it most, without hidden costs or confusing red tape.'
Whether serving seniors or younger individuals with terminal conditions, Excell's care plans are individualized, flexible, and always aimed at preserving the dignity of the patient and the well-being of their families. Locally led and operated, Excell's team includes nurses, therapists, aides, social workers, chaplains, volunteers, and administrative staff who see their work as a calling. This internal culture of collaboration translates into external excellence, where patients receive wraparound care, and families feel supported from the first call to the final farewell.
Looking ahead, Excell reflects on its over 25 years of service and sees the future is filled with opportunity. The company is actively seeking acquisitions and preparing to open new private care and hospice locations throughout Oklahoma to meet growing demand.
'Our goal is simple,' said Warner. 'We want to continue being Oklahoma's go-to resource for life-changing home care and hospice services, known for accessibility, affordability, and always delivering with heart.'
Media Contact
Name: Crystal Warner
Email: [email protected]
Source published by Submit Press Release >> Excell Celebrates Over 25 Years of Delivering Compassionate Home Care and Hospice Support
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
CRISPR Therapeutics (NasdaqGM:CRSP) Sees 16% Stock Price Surge Over Last Month
CRISPR Therapeutics experienced a 15.8% increase in its share price over the past month. While specific recent news on the company was not available to credit for this movement, it's worth noting that during this period, the broader market rose by 1.8%, and has seen a 13% increase over the past year. With market earnings projected to grow 14% annually, the strong performance of CRISPR's stock could be viewed alongside these generally positive trends and any recent but unspecified developments as contributing factors to its upward momentum in the market. Be aware that CRISPR Therapeutics is showing 1 weakness in our investment analysis. Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave. Over the past year, CRISPR Therapeutics' shares experienced a total return of 27.67% decline. This longer-term performance contrasts with the U.S. market's return of 12.6% and the U.S. Biotechs industry return of 9% over the same period. Despite the recent 15.8% increase in CRISPR's stock price over the past month, the longer-term underperformance highlights ongoing challenges. The company's significant net losses and decreasing revenue signal potential hurdles to achieving forecasted revenue growth of 57.32% per year. Earnings forecasts remain bleak, as CRISPR is currently unprofitable and not expected to turn profitable within the next three years. This indicates that while the recent uptick in share price might be aligned with short-term market trends, the company's underlying financial health presents uncertainties. Analyst consensus estimates a fair value price target of US$81.67, which is over twice the current share price. This suggests that the stock is trading at a substantial discount, potentially implying room for future price appreciation if the company can improve its financial metrics. However, it also underscores the risks, given the current unprofitable status and forecasted challenges ahead. Examine CRISPR Therapeutics' past performance report to understand how it has performed in prior years. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGM:CRSP. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Bloomberg
34 minutes ago
- Bloomberg
Vance Says He Hopes Musk Will 'Come Back Into the Fold'
In a podcast interview with Theo Von "This Past Weekend", Vice President JD Vance share his thoughts Musk's exit from the Trump administration and that he hopes Musk will 'Come Back Into the Fold". (Source: Bloomberg)
Gizmodo
34 minutes ago
- Gizmodo
Musk Deletes His ‘Really Big Bomb' Claiming Trump Appears in Epstein Files
In the middle of their very public breakup, a scorned Elon Musk decided to drop a 'really big bomb' on Donald Trump, accusing the president of appearing in the Epstein files. Sometime Saturday, it seems the billionaire decided he wanted to try to disarm that bomb, as he deleted his posts claiming that Trump has links to the famous child sex trafficker. Musk and Trump had been acting catty for a couple of days by the time Musk went nuclear, going back and forth over Musk's opposition to Trump's 'Big Beautiful Bill'—a proposal that includes the largest cuts to Medicaid and food assistance programs in history. Musk objected to the bill, but not because it would be devastating to low- and middle-income households, but seemingly rather because it was going to hurt his own bottom line by ending electric vehicle tax credits that Tesla benefits from. Musk tried to kill the bill by posting incessantly about it, creating a rift among Republicans who will essentially need everyone in the party to be on board in order to get the thing passed. Trump, annoyed, took some shots at Musk for his dissent, which led to Musk just blowing the whole thing up. He said Trump appeared in the Epstein files and 'That is the real reason they have not been made public.' Funnily, he also doubled down by saying, 'Mark this post for the future. The truth will come out.' Those posts are now deleted—though have, of course, been archived, screenshotted, and quoted many times over. So, too, has a post in which Musk supported the idea that Trump should be impeached. He hasn't gotten around to taking down his post claiming that Trump's tariffs will cause a recession, so, it's clear the two aren't fully ready to make up, even if there is a de-escalation. We're also starting to get more of a picture of what has been happening behind the scenes while these two air out each other in public. A report published Saturday by the Washington Post claims that Trump was 'dejected' during Musk's crash out, and tried to rationalize Musk's behavior by calling him 'a big-time drug addict.' Musk had apparently been acting erratically for quite some time (not exactly a shock if you've scrolled through his posts on Twitter for like, 30 seconds), and a reported physical conflict with Treasury Secretary Scott Bessent that saw Musk supposedly throw his shoulder into Bessent was the breaking point where the billionaire started to get pushed out, per the Post. Trump opted not to pour gasoline on the situation—a shocking decision from a guy not exactly known for his restraint—but also is apparently not interested in reconciling with Musk. An official within the administration told the Post that even if they do make up, 'It'll never be the same.'
